Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.81 |
| ▸ | GPR174 | Q9BXC1 | 8/20 | 0.79 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3317049 | 0.90 | MAPT (0.79) | MAPTALDH1A1GPR174LMNAGAA | |
| SCHEMBL22621220 | 0.88 | GPR174 (1.00) | MAPTALDH1A1GPR174LMNAGAA | |
| SCHEMBL22621283 | 0.85 | GPR174 (1.00) | MAPTALDH1A1GPR174LMNAGAA | |
| SCHEMBL10359737 | 0.83 | MAPT (0.65) | MAPTALDH1A1GPR174LMNASMN1; SMN2 | |
| SCHEMBL5989854 | 0.83 | MAPT (0.72) | MAPTALDH1A1GPR174LMNASMN1; SMN2 | |
| SCHEMBL3315404 | 0.83 | MAPT (0.72) | MAPTALDH1A1GPR174LMNAGAA | |
| SCHEMBL16123482 | 0.81 | MAPT (0.60) | MAPTALDH1A1GPR174LMNAGAA | |
| SCHEMBL31739514 | 0.80 | MAPT (0.67) | MAPTALDH1A1GPR174LMNAGAA | |
| SCHEMBL9302533 | 0.79 | GPR174 (0.67) | MAPTALDH1A1GPR174LMNAGAA | |
| SCHEMBL10359736 | 0.78 | MAPT (0.58) | MAPTALDH1A1GPR174LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | MAPT 2130/4885ALDH1A1 649/4885GPR174 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.